Fig. 1: FBP1 inhibits the nuclear translocation of STAT3 via an enzymatic activity-dependent mechanism.

A Box plots comparing FBP1 mRNA expression levels in the Bonome cohort and TCGA cohort were download from the Oncomine database. B Representative images from ovarian cancer and normal ovarian biopsy samples with various levels of FBP1 immunohistochemical staining (4× and 400×). C FBP1 expression in human ovarian carcinoma sections (n = 375, left) and normal ovarian tissues (n = 23, right). D Relationship of FBP1 expression with ovarian cancer chemotherapeutic resistance (χ² test). E Representative ¹⁸F-FDG PET/CT images from ovarian cancer patients with negative (left), weak (middle), or high (right) FBP1 expression (all 400×). F SUVmax of ovarian cancer patients with low-FBP1 expression and metastasis or high-FBP1 expression and no metastasis (n = 100). G Kaplan–Meier DFS and OS curves (log-rank tests) for patients with high and low expression of FBP1 based on IHC staining scores. H Kaplan–Meier DFS and OS curves for patients with high or low-FBP1 expression levels in patients stratified by the tumor stage. I Kaplan–Meier DFS and OS curves for patients with high or low-FBP1 expression levels stratified by present of ascites. J Kaplan–Meier DFS and OS curves for patients with high or low-FBP1 expression levels stratified by present of drug resistance status.